Italia markets closed

AIM ImmunoTech Inc. (0A4Y.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,8200-0,0499 (-5,74%)
Alla chiusura: 02:30PM BST
Schermo intero
Chiusura precedente0,8699
Aperto0,8200
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,8200 - 0,8200
Intervallo di 52 settimane0,8200 - 0,8200
Volume200
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)-0,58
Rapporto PE (ttm)N/D
EPS (ttm)-0,4040
Prossima data utili10 ago 2022 - 15 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

    Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotechnology New Jersey Bioscience Center, NJ New Jersey Bioscience Center,, NJ OCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancer

  • GlobeNewswire

    AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

    Further expansion of patent portfolio supports of the Company’s extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by

  • GlobeNewswire

    AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

    OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26,